Post-Hoc Analysis of a Randomized, Double Blind, Prospective Study at the University of Chicago: Additional Standardizations of Trial Protocol are Needed to Evaluate the Effect of a CXCR1/2 Inhibitor in Islet Allotransplantation

A recent randomized, multicenter trial did not show benefit of a CXCR1/2 receptor inhibitor (Reparixin) when analysis included marginal islet mass (>3,000 IEQ/kg) for allotransplantation and when immunosuppression regimens were not standardized among participating centers. We present a post-hoc a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachul, Piotr J., Golab, Karolina, Basto, Lindsay, Zangan, Steven, Pyda, Jordan S., Perez-Gutierrez, Angelica, Borek, Peter, Wang, Ling-Jia, Tibudan, Martin, Tran, Dong-Kha, Anteby, Roi, Generette, Gabriela S., Chrzanowski, Jędrzej, Fendler, Wojciech, Perea, Laurencia, Jayant, Kumar, Lucander, Aaron, Thomas, Celeste, Philipson, Louis, Millis, J. Michael, Fung, John, Witkowski, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085379/
https://www.ncbi.nlm.nih.gov/pubmed/33908301
http://dx.doi.org/10.1177/09636897211001774

Ejemplares similares

Ejemplares similares